Elevated creatine phosphokinase MB in a patient with neuroendocrine carcinoma of the colon--evidence for a tumor marker. Report of a case.
Elevated creatine phosphokinase (CPK) MB isoenzyme has become accepted as a highly specific criterion for the diagnosis of myocardial infarction (MI). A patient with metastatic neuroendocrine carcinoma of the colon who had marked and persistent elevation of CPK-MB isoenzyme, in the absence of clinical and cardiographic evidence for MI, is described. The CPK-MB level was 25 percent (normal, less than 3 percent) on admission, 39 percent postoperatively, and 57 percent on discharge. A prompt decline in serum CPK-MB activity (11 percent, less than 3 percent) paralleled chemotherapy-induced tumor regression. Resurgence of the isoenzyme heralded recurrent disease. These findings suggest that CPK-MB may be a valuable adjunct marker in the diagnosis and monitoring of neuroendocrine carcinomas.
Rizk
S L
SL
Department of General Surgery, Rush Medical College, Chicago, Illinois.
Roseman
D L
DL
Bonomi
P
P
Sky-Peck
H
H
Clark
J
J
Lee
I
I
Gould
V E
VE
D014408:Biomarkers, Tumor / Q000097:blood*; D002277:Carcinoma / Q000201:enzymology* / Q000473:pathology / Q000628:therapy; D003106:Colon / Q000473:pathology; D003110:Colonic Neoplasms / Q000201:enzymology* / Q000473:pathology / Q000628:therapy; D003402:Creatine Kinase / Q000097:blood*; D006801:Humans; D007527:Isoenzymes; D008297:Male; D008875:Middle Aged
D014408:Biomarkers, Tumor; D007527:Isoenzymes; D003402:Creatine Kinase